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Introduction
The use of antibodies to identify the localization of anti-
gens in cells and tissues has long been one of the most 
powerful and popular tools in cell biology and related dis-
ciplines. when one knows for sure in which cells, and then 
in which organelles an antigen resides, one acquires crucial 
information about the antigen and its potential functions. 
The theory is ‘clean’: one makes an antibody against, say a 
purified protein and the antibody is supposed to bind to the 
antigen like a key fits a lock. It should thus be technically 
straightforward to add the antibody to, say a section of 
cells or tissues and identify unequivocally where the anti-
body binds; which should be the site(s) where the antigen 
is localized. As discussed in more detail below, since there 
are now dozens of companies selling thousands of antibod-
ies against a huge number of proteins (and other antigens 
such as lipids and nucleic acids) at first glance the situation 
‘smells like a rose’. A beginner in the field can be easily 
fooled by this appealing scenario, unaware that a more real-
istic cliché might be—a ‘hornet’s’ nest’!
It is a long and unpredictable route from an antigen that 
needs to be prepared for injection into an animal (most 
commonly a rabbit or a mouse) to the serum or purified 
antibody that is ready to be used for immunocytochem-
istry (ICC); and therefore, antigen X ‘in’ does not neces-
sarily mean anti-X ‘out’. A complex, nonlinear path of 
cell interactions can be traced from the antigen-presenting 
cells that first take up the immunogen, via T helper cells 
through to B lymphocytes. The B cells can be sorted into 
individual clones, each derived from a single cell that 
secretes identical antibodies. when the antibody is made by 
a single clone it is referred to as a monoclonal antibody. 
when a mixture of clones is used, as is the case with virtu-
ally all antisera, the antibody is a polyclonal antibody. Both 
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types of antibodies are widely used for ICC. A beginner is 
well advised to read the excellent monographs on how to 
make and characterize antibodies by Harlow et al. (1988) 
and Frank (2002) that are especially relevant for use in 
immunocytochemistry. For general reviews on immuno-
cytochemistry procedures and theoretical background see 
Ramos-vara (2005), Dalcik and Dalcik (2012) and Griffiths 
et al. (1993).
It must be appreciated from the outset that only a minor-
ity of antibodies are useful for immunocytochemistry. 
Looking at the complexity of the interactions that are nec-
essary for making an antibody, it may not be so surprising 
that the success rate is far from perfect. A glimpse at the 
details of how antibodies actually bind protein antigens 
makes it evident that the situation is even more complex. 
According to Frank (2002) an epitope in a protein may 
encompass about 15 amino acids but only about five of 
these contribute to the binding energy. On the other hand, 
the part of the antibody that binds the epitope is the par-
atope, a part of the antibody variable region, which com-
prises about 50 amino acids. Similarly, each paratope has 
about 15 amino acids of which about five contribute to the 
binding energy for the epitope. Frank stated that ‘Paratopes 
and epitopes define complementary regions of shape and 
charge rather than particular amino acid compositions’; and 
‘A single paratope can bind unrelated epitopes and a sin-
gle epitope can bind to unrelated paratopes’ (Frank 2002). 
Thus, it is possible that a single paratope can bind two 
unrelated peptides (mimitopes), or a particular epitope can 
be recognized by two different paratopes with no sequence 
similarity.
A serious consequence of these facts is that an antibody 
against a defined antigen, e.g., a whole purified protein or a 
peptide, could bind to structurally related antigens that have 
a completely or partially different amino sequence (molec-
ular mimicry). This means that, predicting an antibody has 
high affinity for the immunizing antigen is extremely dif-
ficult if not impossible. Such molecular mimicry has been 
convincingly demonstrated for antibodies made against 
well-defined, small molecule chemicals such as 2,4-di-
nitrophenol (DNP), a favorite of immunologists. varga 
et al. (1991) tested a mouse anti DNP-Ige antibody (SPe7) 
against a library of over 2,000 compounds and identified a 
number of unrelated chemicals which were able to compete 
with DNP for binding to SPe7. In a more detailed study of 
the same antibody by James and Tawfik (2003), it was con-
firmed that the antibody had a high affinity to DNP, but not 
to closely related chemicals. However, a number of totally 
different chemicals were also able to bind with high affinity 
and they selected a few for X-ray crystallographic studies 
of the antigen–antibody complexes. Crucially, this revealed 
that each chemical bound in a specific manner with dif-
ferent stereochemistry by hydrogen bonding to different 
residues located within the antibody binding site. Thus, 
even with these small, well-defined, molecules the ligands 
that would bind specifically could not be predicted a priori.
There are also multiple examples of similar cross-reac-
tivity of antibodies made against a particular protein that 
cross-react, seemingly specifically, to both related and 
unrelated antigens. For example, Frank (2002) cites Les-
car et al. (1995) who used X-ray crystallography to study 
the physical contact site between guinea fowl lysozyme 
and two different antibodies. while both these antibodies 
engaged with the same 12 amino acids of the antigen, they 
contained two different paratopes—with no identical amino 
acids in the region that binds the antigen. Crucially, the two 
antibodies also had different patterns of cross-reactivity.
If the situation is so unpredictable for antibodies bind-
ing to simple antigens, it can be appreciated that we are 
approaching ‘no man’s land’ when it comes to the use of 
antibodies on sections or whole mounts that have been sub-
jected to the conditions needed for immunocytochemistry 
(aldehyde cross-linking, embedding, antigen retrieval, etc.). 
The use of specificity tests discussed below has neverthe-
less identified clear examples of antibodies that bind in 
a way that can be described as ‘specific’, by many crite-
ria to antigens totally unrelated to the initial immunizing 
antigens. For example, Holmseth et al. (2005, 2006, 2012) 
made dozens of different antibodies against transporters of 
the excitatory neurotransmitters eeAT2 and 3 (these stud-
ies revealed a rich treasure of problems related to the topic 
of this review, using all the best controls). Relevant here 
is their example of anti-peptide antibodies raised against 
eeAT3, of which some cross-reacted with high affinity to 
an unrelated protein tubulin. Importantly, while these anti-
tubulin antibodies could be removed effectively by affinity 
purification against tubulin, one antibody retained specific 
binding to both eeAT3 peptide and tubulin after this treat-
ment. It should be noted that the adsorption method is only 
applicable to polyclonal antibodies; monoclonal antibodies 
are by definition identical.
A number of examples have been published illustrat-
ing how aldehyde fixation used for microscopy induces the 
presence of new epitopes in sections that are unrelated to 
the starting antigen. A striking example was described by 
Josephsen et al. (1999). These authors showed that a mon-
oclonal antibody against vimentin showed a selective and 
strong cross-reaction to unrelated tooth enamel proteins, 
amelogenins. A series of experiments made the convinc-
ing case that the ‘new’ reactivity was induced by aldehyde 
cross-linking of the tissue; this notion was supported by 
experiments in which fixed and unfixed western blots were 
compared before antibody labeling.
Another excellent example of the subtle issues of anti-
body specificity comes from the work of watanabe et al. 
(1998). These authors addressed the localization of the 
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NR2A glutamate receptor in the mouse hippocampus. 
when they initially compared aldehyde-fixed sections of 
brain tissues from wild type (wT) and mice knocked out 
(KO) for NR2A they saw a similar cytoplasmic labeling 
by immunofluorescence labeling of both tissues. However, 
when they tested the antibody after treating the sections 
with proteases (pepsin or proteinase K), they saw what was 
interpreted as a specific membrane-bound labeling in the 
wT that was missing in the KO sections. A similar exam-
ple of apparent specificity of antibody that was revealed for 
immunofluorescence on sections of mouse cortex after pep-
sin treatment was described by Lorincz and Nusser (2008) 
for a potassium channel protein Kv1.2. These authors 
speculated that the protease treatment removes proteins 
that block access of the antibody to the specific antigen in 
the sections; this is an example of ‘antigen retrieval’, com-
monly used approach for, e.g., neurobiology and pathol-
ogy (but not often in cell biology). The main take home 
message here is that success in providing convincing evi-
dence that an antibody is specific for an antigen can be 
unpredictable.
In summary, rather that representing the classical view 
of one antibody binding to a protein like a key fits a lock, 
these, and many other examples we have not cited, lead 
us to the conclusion that the ‘key’ may fit many types of 
‘locks’ and the lock can fit an array of different keys.
The problems with primary antibodies
Our focus here is on the primary antibodies that are the 
main problem when assessing specificity; for a good, 
concise introduction to the problem see Saper (2009). 
In most protocols, the primary antibody is detected by a 
generic second antibody attached to a visualizing marker. 
For example, a rabbit primary antibody against X can be 
detected by a goat anti rabbit secondary antibody con-
jugated to a fluorochrome or a colloidal gold conjugate. 
Obviously, it is also important that the secondary antibod-
ies are specific but, in practice, this is far less of a problem 
than the issue of primary antibody specificity. The key con-
trol is to add all the secondary, and tertiary reagents in the 
absence of the primary antibody.
The concern with secondary antibodies, especially when 
used for double labeling, is inter-species cross-reactivity. 
Reagents are available which are specifically adsorbed 
against immunoglobulins of other species. However, cross-
reactivity, in particular with rabbit antibodies to infec-
tious agents such as Mycobacterium spp. and Rhodococ-
cus spp., is a serious issue and in our experience cannot be 
reduced, not even with pre-adsorption against these organ-
isms or their homogenates (Urska Repnik and G. Griffiths, 
unpublished data). Some of these problems may be due to 
mycobacterial cell wall components in Freund’s adjuvant 
that used to be commonly used in preparing polyclonal 
antibodies. However, we have also seen cross-reactivity 
with monoclonal antibodies where this adjuvant was not 
used.
For any ICC approach for light microscopy or eM, the 
cells and tissues need to be subjected to a series of prepara-
tion protocols, including fixation, detergent permeabiliza-
tion, embedding, sectioning before the antibody reaction 
steps. The examples above of significant effects of alde-
hyde fixation and antigen retrieval on immunolabeling is 
only a glimpse into a whole world of complexity in which 
all the preparation steps can positively or negatively influ-
ence the final result and the reliability of that result. A key 
issue here in dealing with ICC is providing evidence about 
specificity which is based as much as possible on the actual 
conditions in which the antibody labeling is carried out.
Another crucial issue that is often not taken seriously 
enough is that a solution of IgG in a test tube is not a sim-
ple chemical but a complex protein that can aggregate, 
be subjected to proteolysis, undergo denaturation or stick 
to the surface of the tube. even under the best conditions, 
antibodies can lose activity with time, further complicating 
the issue of deciding when an antibody labeling is ‘real’. In 
one’s own lab one has some control over this issue but with 
commercial antibodies (see below) one is at the mercy of 
the company. Figure 1 gives some suggestions as to how 
antibodies should be stored.
Transporting antibodies in tiny aliquots is also a prob-
lem. An excellent system for storing and transporting 
antibodies, even in 1 μL aliquots has long been used by 
Heinz Schwarz (personal communication); this involves 
Storing antibodies
Fig. 1  Tips on antibody storage
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flame-sealing the antibody in glass micropipettes. These 
can be stored for many years at −20 °C.
The problem of providing (preferably unequivocal) 
evidence justifying the assumption that an antibody used 
for ICC is ‘specific’, is analogous to the problem that the 
police and the justice system have in identifying a potential 
murderer, and then in proving ‘beyond reasonable doubt’ 
that the accused is indeed guilty of the crime. The system 
needs to take into account all available evidence that sup-
ports the hypothesis that the accused is guilty, or not. Some 
evidence, such as a motive might be given less weight than, 
say solid DNA-based evidence found at the scene of the 
crime, but it is still the sum-total of all the evidence which 
the judge or the jury uses to make a decision.
So it is with antibodies. It is often very difficult, if not 
impossible to prove beyond all reasonable doubt that, under 
the conditions used for the ICC reactions, a particular anti-
body is specific for the true target antigen. It is therefore 
important to collect supporting or contradictory evidence 
from all possible sources. Some of this can be given more 
weight than others. we will summarize the main types of 
evidence that can be used.
Criteria that can be used to assess specificity and the 
potential problems associated with them
 1. The antibody against antigen X gives a reproducible 
and compartment-selective labeling pattern. This is 
a crucial starting point because without this, there is 
nothing to evaluate. The pattern may not be readily 
discernable by ‘eye’ and below we describe quantita-
tive methods available for finding patterns in immu-
nogold labeling.
Problems: The labeling may be associated with struc-
tures not containing the real antigen.
 2. This labeling pattern should be consistent with infor-
mation about the antigen from other sources. For 
example, the presence of a signal sequence and mem-
brane-spanning domain would indicate it should be 
found in membranes.
Problems: The biological information may be wrong 
or misleading.
 3. The labeling is lost in a knockout (KO) animal or cell 
reduced in a knock down situation (e.g., using si or sh 
RNA). As discussed in more detail below a consensus 
is emerging that this is the most informative control, 
when available.
Problems: Deletion of a gene may lead to up-regula-
tion of related gene products that might cross-react 
with the antibody. There may already be cross-react-
ing antigens in the KO animal. There may be changes 
in cellular structures or compartments that confound 
the identification or quantification of structures or 
compartments. It is obviously important that the KO 
procedure does not lead to expression of non-func-
tional proteins. For subtle, predictable and unpredict-
able artifacts see Holmseth et al. (2006, 2012), Burry 
(2011), Lorincz and Nusser (2008). It should be noted 
that all antibodies, including monoclonals can show 
cross-reactivity to off-target antigens (Holmseth et al. 
2012; Nigg et al. 1982).
 4. If the protein can be expressed or over-expressed in a 
cell or organelle not expected to contain the antigen, 
there should be a corresponding increase in labeling 
in some structures (Saper 2009). This control is seen 
as comparable to the KO control.
Problems: Artificial expression and even more likely, 
over-expression may lead to mis-localization of the 
protein. For example, a peripheral membrane protein 
may become displaced to the cytoplasm (Soderqvist 
et al. 1996). Again there may be modifications to the 
very compartments that are used for the evaluation 
including those that really hold the antigen and those 
that don’t. Changes in these compartments can then 
produce changes in density or quantity of the labeling 
signal.
 5. If the protein can be expressed as a GFP construct 
the pattern of GFP expression should correlate with 
the labeling of an antibody against the same protein 
(Burry 2011). The use of an antibody against GFP can 
also be a powerful tool in this context. Other tags such 
as myc, FLAG or HA may be used instead of GFP. 
The use of cell lines stably expressing these tagged 
constructs at low levels can reduce artifacts of overex-
pression. The tags can also be expressed as an RNAi 
resistant tagged construct while at the same time 
allowing parallel knockdown of the endogenous back-
ground expression.
Problems: There is no guarantee that the GFP-linked 
protein will localize faithfully, especially when over-
expressed.
 6. Independent methods for separating the antigen from 
other antigens, derived from the cells or tissues of 
interest, such as one-dimensional or two-dimensional 
western blots (wB) or thin layer chromatography, 
should give an identification pattern on the separated 
antigen (e.g., the expected molecular weight band(s)) 
that is consistent with the known biology/biochemis-
try of the antigens.
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Problems: There is the fundamental problem that 
WB recognizes SDS-denatured antigens whereas 
aldehyde-fixed proteins for immunocytochemis-
try are closer to being in the native state (Griffiths 
et al. 1993). There are many examples of wB giv-
ing results that are mis-leading for interpretation of 
antibody specificity for immune-labeling (Holmseth 
et al. 2005, 2012). Almost all commercial antibod-
ies give some kind of reactivity by wB but far fewer 
(are claimed to) label for ICC. A single band by wB 
may have dozens of different protein species when 
analyzed by mass-spectrometry (Thiede et al. 2013) 
or multiple spots on 2D gels. Additional problems 
associated with gel separation methods in general is 
that only those antigens that enter the gel and separate 
from other components are identifiable. For a detailed 
discussion on the use and pitfalls of wB for determin-
ing antibody specificity (Holmseth et al. 2006).
 7. when the antigen is a peptide, the pure peptide may 
be able to compete with the antibody for binding anti-
gen. The amount of labeling should be reduced or 
eliminated when the peptide and antibody are added 
together to the sample to be labeled.
Problems: This pre-adsorption approach may block 
not only ‘specific’ antigen binding to antibody but also 
the binding of unrelated, cross-reactive epitopes (‘off-
target’ antigens). while this control used to be given 
much ‘weight’ in terms of evidence of specificity (e.g., 
Petrusz et al. 1976) more recent authors have illus-
trated many, often subtle examples of antibodies that 
are found to be unspecific since they show labeling 
(and often bands in wB) in KO animal tissues but nev-
ertheless ‘pass the pre-adsorption test’; in this case, the 
peptide blocks both ‘specific’ and cross-reactive anti-
gens (Holmseth et al. 2005; Burry 2011; Swaab et al. 
1977; Saper and Sawchenko 2003; Pradidarcheep 
et al. 2009). The affinity of the antibody for an antigen 
in a protein may also be much higher than for the free 
peptide. In that case, the antibody may be specific but 
the pre-adsorption test fails to reveal it.
 8. Two or more independent antibodies made against 
X should give the same or similar labeling pattern. 
If these are peptide antibodies, ideally these should 
be against non-overlapping sequences in the protein 
(Rhodes and Trimmer 2006). Problems: Two or more 
antibodies may recognize the same antigen, as well as 
the same, unrelated cross-reactive molecule (Holm-
seth et al. 2012).
 9. The pre-immune serum should not show a reaction. 
This is important for antigens from infectious organ-
isms that may have infected the immunizing animal 
before the immunization. Also when host cells infected 
with these infectious organisms are labeled, part of the 
signal can be due to cross-reactivity with the patho-
gen. This is often difficult to notice, especially with 
light microscopy and when a host antigen is expected 
to localize close to the pathogen, for example on the 
phagosome or vacuole membrane surrounding a path-
ogen. we have observed cross-reactivity in particular 
with rabbit primary, as well as secondary polyclonal 
antibodies with infectious agents such as Mycobacte-
rium spp., Rhodococcus spp., Plasmodium spp. and 
Babesia spp. (Repnik and Griffiths, unpublished data).
Problems: Except for antibodies against infectious 
organisms this control only provides crude informa-
tion that the antibody reactivity is somehow related to 
the original antigen that was used for immunization. 
Pre-immune serum is anyhow not readily available 
from companies that sell antibodies.
 10. At the tissue level, the combination of immunocy-
tochemistry and in situ hybridization can provide 
important supporting information about the antibody 
when the localization of mRNA for a protein cor-
relates with the localization of an antibody (Rhodes 
and Trimmer 2006) but see (Burry 2011). If the cells/
tissue of interest can be isolated, the use of RT-PCR 
can also be valuable to detect the gene product at the 
mRNA level.
Problems: The methods used for in situ hybridization/
PCR are generally different and harsher than those 
used for immunolabeling (Burry 2011). The pres-
ence of mRNA does not guarantee the expression of 
the protein of interest or indeed the level of expression 
that might be needed for the detection of the protein 
of interest. The level of mRNA expression may be very 
much lower and possibly undetectable.
even in the best cases, with optimal specimen prepa-
ration, an accessible antigen and a highly specific, high 
affinity antibody there is still a threshold of antigen below 
which it cannot be detected (Griffiths et al. 1993; Fritschy 
2008). Given the unpredictability in antibody–antigen inter-
actions in situ such as on sections it is difficult to estimate 
what this lower level of detection can be. If the amount 
of primary antibody that binds a section is relatively low, 
a positive signal for this bound antibody can be detected 
more sensitively using small fluorochrome labeled second-
ary antibodies and immunofluorescence than they can by 
those attached to bulkier gold particles; the latter are known 
to be less sensitive as they increase in size (Schwarz and 
Humbel 2007). If one is below the detection threshold with 
the primary antibody for the antigen, the only way out is 
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to over-express the protein. However, that approach brings 
its own problems. If the antigen is in a defined structure 
like the nuclear pore complex, where each pore can only 
accommodate a defined number of proteins, increasing the 
amount of these proteins may lead to its mis-localization to 
the cytoplasm, eR or nucleus (Soderqvist et al. 1996; Bas-
tos et al. 1996). Another way is to increase the signal by 
collecting it from as large an area of sample/section as is 
possible. This is possible with gold particle labeling in eM.
The provenance of the antibody and the biology of the 
system
Before one decides to try to localize an antigen by ICC one 
must have a rational biological question, or questions to 
address. One must know something about the antigen even 
before one attempts to make, or buy an antibody. The more 
one knows from the outset the easier it is to have a starting 
hypothesis as to where the antigen might be localized, and also 
important, where it might not be expected. This facilitates the 
evaluation of the antibody if some structures (not expected 
to contain the antigen) do not label while other structures 
(predicted to contain the antigen) do label. In the simplest 
instance, an antibody against a membrane protein should not 
label the nuclear matrix. It is obviously much easier to do this 
at the eM versus LM level because more information is avail-
able in the system. The eM approach can also facilitate the 
selection of the optimal concentration of antibody. Of course, 
if the starting hypothesis is wrong, the situation becomes more 
complex and other information must be sought.
The predicted protein sequence might suggest clues. 
Thus, a membrane protein, or from a sequence-predicted 
membrane protein, would be expected to be localized on 
membranes. Similarly, the presence of a secretion signal 
sequence would predict a localization outside the cytoplasm 
(e.g., eR, Golgi, endocytic organelle, extracellularly).
These days, perhaps the most common route to an anti-
body is to make peptides from the known sequence. There 
are a number of algorithms available based on known expe-
rience of what kinds of sequences are most likely to give 
an immune response, e.g., expasy (http://www.expasy.
org/tools/) IeDB website (http://tools.immuneepitope.org/
tools/bcell/iedb_input), or Antigen Profiler (http://www.
pierce-antibodies.com/custom-antibodies/peptide-design-
antigen-profiler.cfm). In general, sequences predicted to be 
on the 3-D surface of the protein are favored. Many com-
mercial companies now offer sequence prediction and pep-
tide synthesis as part of their routine service. As has been 
pointed out by many authors and editors of Journals, it is 
imperative to describe the sequences used when one pub-
lishes about the use of an antibody, as well as all other rel-
evant background information (Fritschy 2008; Saper 2005). 
If the antigen has been purified or is part of a more com-
plex mixture the details of how it was prepared and used 
to immunize the animal needs to be specified, as should 
the question whether the immunocytochemical product 
used was a monoclonal or polyclonal antibody. If the lat-
ter, did one use the serum, IgG fraction or affinity-purified 
antibody after passing the serum over a column, or using 
affinity beads bound to the original antigen or, perhaps, 
protein A? As pointed out by Rhodes and Trimmer (2006) 
there is no hard and fast rule for determining if purification 
is needed, but in general the specificity of polyclonal anti-
bodies improves with purification. It must be pointed out 
that given the harsh reagents needed to remove the bound 
antibodies from columns, one may fail to elute the highest 
affinity antibodies that, in contrast, would be present in the 
antiserum.
when one makes an antibody from a peptide the carrier 
used to conjugate the peptide is important for immuno-
genicity but may cause problems with respect to retrieving 
the most specific antibodies from a serum. The most com-
mon method is to affinity purify the serum over a column 
with the peptide immobilized on beads, a procedure that is 
most efficient when the peptide is conjugated to a protein, 
such as keyhole limpet hemocyanin (KLH; Daniel Louvard, 
personal communication). KLH, a large copper-containing 
protein of multiple subunits of 350Kd has become popular 
as a carrier protein because it is highly immunogenic and 
expressed only in arthropods and molluscs. It is therefore 
evolutionary far from mammals; this is considered impor-
tant in reducing the incidence of false positive reactions 
that are more likely to occur with mammalian carrier pro-
teins such as BSA (bovine) or ovalbumin (Chicken eggs).
Polyclonal versus monoclonal antibodies
Both polyclonal and monoclonal antibodies are widely 
used for immunocytochemistry. In general, polyclonal anti-
bodies are more often successful for immunocytochemistry 
than monoclonals. This is to be expected since polyclonals 
are derived from a family of B cells and recognize many 
different epitopes on the same protein, whereas monoclo-
nals, derived from a single B cell clone are specific for sin-
gle epitopes. In our experience, the best monoclonals are 
those available as the culture supernatants of the hybridoma 
cells; these are diluted no more than 1:10 with the block-
ing solution. A big theoretical advantage of monoclonals is 
that each batch must have the same specificity and the sup-
ply is unlimited. In contrast, no two batches of polyclonal 
antibody can be expected to be identical and the supply of 
any one batch is limited. This lack of reproducibility and 
sustainability of the supply is a severe problem with com-
mercial sources of polyclonal antibodies.
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The problems with commercial antibodies
According to Bordeaux et al. (2010) there are now over 
180 commercial companies that sell around 350,000 anti-
bodies to the scientific community (http://www.antibody
resource.com/onlinecomp.html). This is one of around 20 
important publications that have started to question the fact 
that has long been apparent to anyone with experience in 
purchasing and using commercial antibodies, especially for 
immunocytochemistry: a significant fraction of commercial 
antibodies appear to be ‘no better than PBS’ (Couchman 
2009). Since most of the critical comments have been in 
particular fields, such as neurobiology, physiology, pathol-
ogy and cancer diagnostics we suspect most of these pub-
lications will not have been seen by many cell biologists, 
even those that are heavy users of commercial antibodies. 
The facts are collectively very disturbing—at worst almost 
entire fields of research have been led down wrong paths 
by use of a few prominent commercial antibodies that were 
later discovered to be nonspecific or of dubious specific-
ity. One important thread that links all of these, mostly 
recent publications is the powerful use of knockout animals 
which, despite the theoretical problems raised above, are 
increasingly being accepted as the ‘gold standard’ for anti-
body specificity. Other criteria summarized above also play 
important supporting roles in this ongoing ‘detective story’.
One issue of Naunyn-Schmiededberg’s Archives of 
Pharmacology has six articles that collectively deal with, 
mostly widely used commercial antibodies against an 
array of membrane receptors that are demonstrated to lack 
the required level of specificity for immunocytochemistry 
[summarized by Kirkpatrick (2009)]. The first paper (Jos-
itsch et al. 2009) focused on five types of muscarinic recep-
tors (M1R-M5R) that bind acetylcholine. They tested 24 
commercial (four different companies) and ‘home-made’ 
antibodies using IF on cryostat sections of wild type mice 
and mice deficient for the five receptor sub-types. Six-
teen of these antibodies were tested in detail using a total 
of 456 different antibody/different protocol combinations. 
Together with four different dilutions of each antibody 
this meant they had to test over 1,800 different conditions. 
Kirkpatrick states ‘with two exceptions (anti-M2R), how-
ever, all antibodies produced identical immunohistochemi-
cal labeling patterns in tissues taken from corresponding 
gene-deficient mice, even when the pre-absorption control 
(with peptides) suggested specificity’ (the latter problem 
has been discussed above-criterion 8).
In the same Journal issue, Lu and Bartfai (2009) focused 
on immunolocalization of G-protein-coupled receptors for 
the neuropeptide galanin (GalR1 and 2) and took advantage 
of KO mice and commercial polyconal antibodies against 
peptides specific to the two receptors from three different 
companies. Strikingly, all the antibodies gave essentially 
indistinguishable pattern of labeling on cryostat sections 
and western blots between wT and KO mice. A similar 
result was seen in the next article by everaerts et al. (2009) 
who tested three antibodies against the transient recep-
tor potential cation channel vanilloid sub-family member 
(TRPv-1). All antibodies from three different companies 
gave a similar labeling pattern in sections of KO and wT 
mice.
Three more papers in the same issue provided western 
blotting data revealing that antibodies to muscarinic and 
adrenergic receptors (Jensen et al. 2009) gave multiple 
bands by western blotting in KO tissue. An over-expres-
sion, transfection approach was used for antibodies against 
dopamine receptors by Bodei et al. (2009) who came to 
the same conclusion: lack of specificity. while it must be 
emphasized again that lack of specificity on blots is not 
the same as proof of lack of specificity for immunolabe-
ling, the fact remains that the majority of commercial anti-
bodies are claimed above all else to be specific by western 
blotting. It must also be pointed out that in the four stud-
ies combined, a total of over 30 antibodies were deemed to 
lack specificity.
In a more recent, comprehensive analysis of six com-
mercial antibodies against the angiotensin II AT1 recep-
tor from three companies Benicky et al. (2012) compared 
wT and KO mice. By the criteria of tissue section IF, by 
expressing (or not) antigen in cells lacking antigen and by 
western blotting all six antibodies were concluded to be 
nonspecific. Again, these authors found that pre-absorption 
of antibodies with the immunizing peptides led to a loss of 
labeling (false negative data) that was not consistent with 
the (more convincing) other results. ‘A related problem, not 
only in datasheets of scientific publications is the ‘trick’ of 
illustrating only a cut-out band of interest and not show-
ing the annoying ‘additional bands’. Or as stated by Pra-
didarcheep et al. (2009) in their study of muscarinergic and 
adrenergic receptor localization ‘our immunoblots (based 
on whole cell extracts) show numerous bands for each anti-
serum, whereas those shown in a supplier’s catalog often 
show a single band only’.
The P2X7 receptor that binds extracellular ATP on cell 
surfaces has been widely analyzed using antibodies against 
the intracellular and extracellular domains of the mouse 
receptor from the company Alomone laboratories. How-
ever, a detailed review by Anderson and Nedergaard (2006) 
summarizes the body of data showing that these antibodies 
gave a selective labeling and the presence of multiple bands 
in tissues on KO animals.
Yu and Hill (2013) addressed the specificity of related 
receptors to UDP, P2Y6 receptor in bladder smooth mus-
cle. ‘Three commercially available antibodies to P2Y6 
receptor gave clean bands on western blot which were 
eliminated by specific peptide competition. Two of the 
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three also immune-stained bladder smooth muscle cells 
while leaving adjacent interstitial cells of Cajal unstained. 
However, attempts to validate the specificity of these anti-
bodies by performing the same assays on bladders from 
P2Y6 knockout mice were unsuccessful. In western blots, 
all three antibodies bound similar proteins in both wild type 
and P2Y6 knockout tissue. Immunostaining of knockout 
tissue sections also showed no difference in staining pat-
terns or intensity’. This problem with commercial antibod-
ies is summarized also in a recent article by Buckingham 
(2014; http://www.labtimes-archiv.de/epaper/LT_14_01/
files/assets/common/downloads/LabTimes_2014_01.pdf).
Data sheets provided by commercial companies often 
lack important information and can even be misleading. 
Specificity for antibodies is definitely related to the con-
centration of IgG used experimentally (1–10 μg per ml is a 
reasonable range). Hence a preliminary set of experiments 
is needed to test and adjust cautiously the optimal dilutions. 
To demonstrate antibody specificity, companies often use 
cells overexpressing the protein; the abundant protein gives 
a single band on the blot, whereas detection of endogenous 
proteins may be a lot more difficult and the problem of 
poor specificity of the antibody becomes more prominent. 
Data sheets can also show results obtained several years 
ago. In particular, in the case of polyclonal Ab, it is not 
likely that the same serum is still available, so the image in 
the datasheet may be unrepresentative of the reagent actu-
ally available. Fluorescent images of immunocytochem-
istry results are shown at low magnification, so the signal 
appears strong and the whole cell is glowing. But these 
images fail to demonstrate subcellular localization and thus 
give no information about the specificity of the signal.
Can one do anything to avoid buying useless antibodies? 
The review by Bordeaux et al. (2010) is an eye-opener into 
this, obviously very annoying issue. In an in silico exercise, 
they decided to select seven companies selling antibodies 
against the randomly selected molecule AMP kinase-β 1, a 
cytoplasmic enzyme involved in energy metabolism, simply in 
order to compare the level of background information avail-
able. even though the commercial sources were not identified 
the difference between the worst (company 1) and the best 
companies (6 and 7) was especially revealing. Company 1 in 
fact was more prominent for what it did not reveal, such as 
the sequence of the immunizing peptide [this is apparently not 
an uncommon problem—see Saper (2005)] In contrast, com-
panies 6 and 7 provided a wealth of important information in 
their accompanying data sheets, including publications using 
the antibodies, examples of use of KO cells, western blotting 
and immunocytochemistry under a variety of conditions and 
giving recommended conditions such as antibody dilutions 
for different approaches. This makes the important point that 
it pays to do one’s homework before deciding where to buy an 
antibody! This point is also emphasized further by Kalyuzhny 
(2009) who writes an interesting article on the issue of com-
mercial antibodies from the perspective of the manufacturer. 
He advises the purchaser to even contact the companies for 
advice and for knowledge of available technical support 
before buying the antibody. It may even be possible to strike 
a deal with the company in which one pays only after initial 
testing of a small aliquot or one receives rolling credit if anti-
bodies do not work in exchange for details of the methods 
used. Of course, given the theoretical background we have dis-
cussed and the almost complete unreliability of a priori predic-
tion of how an antibody will behave, there is no way that even 
the most reliable and professional manufacturers can provide 
a complete guarantee of success, any more than one can do so 
when one prepares one’s own antibodies.
EM: an effective quantitative tool for use 
with commercial antibodies
Given the challenging state of the art for commercial anti-
bodies we have described above, it is incumbent on the 
investigator to make a smart choice and careful use of these 
tools. In the context of the foregoing discussion, we will 
now outline how best to evaluate, test and use antibodies 
in immuno-eM, a method that is currently the technique of 
choice for questions related to protein localization.
Although immunofluorescence microscopy (IF) of cells 
and tissue sections is perhaps the dominant approach used 
in most cell biology labs today, there are a number of advan-
tages in using immuno-eM on thin sections. First, it is gen-
erally accepted that one sees more ‘details’ by immunogold 
labeling when compared to the IF (or peroxidase-based) 
methods used in light microscopy. Second, when monitor-
ing immunogold labeling on cell or tissue sections, one sees 
the immunogold signal and also the profiles of all the struc-
tures in the cells (the reference space). By contrast, with IF 
one analyses the localization of one or two antigens (the IF 
signal) against a ‘black’ background, The increased structural 
information provided by eM then makes it easier to decide 
where all the gold particles are localized; for example an 
antibody against a membrane protein should be localized 
within two 10 nm particle widths from a membrane (Griffiths 
et al. 1993). An additional advantage is the digital nature of 
the gold signal which makes it easy to count and quantify, 
whereas quantitative analysis of light microscopy immunocy-
tochemistry is problematic. The combined use of digital, all 
or none, immunogold labeling, combined with the high preci-
sion in allocating them to defined structures make this system 
ideal for minimally biased and efficient quantitative analyses 
using stereology-based methods (Lucocq 2008, 2012).
It should be noted that, even for IF, the use of thin sec-
tion analyses of plastic or thawed cryo sections can pro-
vide more information than do standard (relatively thick) 
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confocal slices. This is because one can use phase contrast 
and other methods to analyze the reference space (Schwarz 
and Humbel 2007). Furthermore these extremely thin sec-
tions will also provide good vertical and horizontal reso-
lution, and nonspecific background labeling is easier to 
notice than in whole mount IF. An additional advantage is 
that fluorochrome-conjugated reagents are smaller than col-
loidal gold reagents and so the labeling is less likely to fail 
because of steric hindrance, often a problem with immuno-
gold labeling (Schwarz and Humbel 2007). In our experi-
ence, on-section IF is also very suitable to test antibodies 
because the cell interior is uniformly exposed by section-
ing. In our view, IF on sections is an under-used yet impor-
tant ancillary method for initial assessment of antibodies.
we will now briefly summarize relevant aspects in eval-
uating and testing new antibodies for use in immuno-eM. 
we will then go on to describe methods we have developed 
for assessing and quantifying patterns of immunogold labe-
ling and finally describe a method for assessing specificity.
Evaluation of commercial antibodies
when searching for an antibody from a commercial source 
one is faced with the dilemma of which characteristics to 
consider as most important (summarized in Fig. 2). As 
already discussed, polyclonal antibodies are to be preferred 
over monoclonals because the multiple epitopes are more 
likely to survive the processing procedures of immuno-eM. 
Furthermore, many polyclonal antibodies are made in rab-
bits, and bind protein A-gold, which is a robust and depend-
able second-step reagent. A second factor in antibody choice 
is species specificity for which commercial information can 
be based on wide variety of evidence. At one end of the spec-
trum, a company may simply state the species from which 
the antigen (or its sequence or peptide) used to generate the 
antibody is derived; at the other the company may addition-
ally provide biochemical or other evidence that the antibody 
actually interacts with the antigen from that species. what-
ever the evidence present the species information can never-
theless be very useful for the customer who can investigate 
compatibility in other species independently by screening 
databases for sequence similarity to original antigen.
As we have emphasized here, the key characteristic of 
antibody specificity is usually poorly evidenced for many 
commercial antibodies. evidence for specificity is mostly 
provided by immunoblot (or immunoprecipitation) data, 
although this there is an increasing trend for this to be sup-
ported by pictorial ‘pretty-picture’ evidence for a staining 
pattern by immunofluorescence or immunocytochemistry 
on paraffin sections. Indeed, when the distribution resem-
bles the ‘predicted’ organelle distribution from experi-
mental or sequence data this is encouraging, although as 
we have already discussed, not necessarily conclusive. 
To date, it is extremely rare for patterns of immuno-eM 
studies to be reported, but independent searches in the lit-
erature can be very useful to identify studies in which the 
same antibodies have already been used. worryingly, it is 
also extremely unusual for companies to report results of 
peptide inhibition studies and sadly even rarer for them to 
report KD/KO data.
Quantifying gold labeling in immuno‑EM
The method of choice in immuno-eM is on-section labe-
ling because it ‘opens up’ cell compartments by preparing 
Antibody type
Specificity evidence
Evaluation
Purchase agreement
Chemical fixation
(Compatibility)
KD/KO   Peptide   Preimmune IP  IB
IEM IF IHC
Pc (r) Mc (m) other
Species specificity Same sp Seq ID other
Return Exchange Other
Fig. 2  evaluation of commercial antibodies. The figure summa-
rizes factors to consider prior to purchasing antibodies with the 
most important characteristics listed to the left of each row. For the 
purposes of immuno-eM, polyconal (Pc) antibodies are preferred 
because they bind multiple epitopes and have maximum likelihood to 
withstand aldehyde cross-linking used for specimen preparation. Rab-
bit (r) antibodies are preferred for immuno-eM because they inter-
act with the general second-step reagent protein A-gold. Monoclonal 
antibodies (Mc) from mouse (m) can be localized with well-charac-
terized intermediate antibodies or antibody gold complexes. Species 
specificity is often stated by companies but likely interactions of anti-
bodies from other species can sometimes be assessed before purchase 
by comparing published gene/protein sequences of intended target 
epitopes with company-specificity data (Seq ID). The main issue 
considered here is antigen specificity and a powerful determinant is 
data showing that labeling is reduced or ablated using knockdown/
knockout (KD/KO). This control is rarely quoted. Some supporting 
evidence may come from peptide inhibition experiments or more fre-
quently by light microscopy pictures showing the pattern of labeling 
(IF/IeM). Specific binding to the target in independent biochemical 
assays (immunoprecipitation, IP; immunoblotting, IB) are less valu-
able for using antibodies for immune-labeling. Further factors to con-
sider before purchase are the preservation of antibody–antigen inter-
actions after fixation/processing methods such as immuno-eM (IeM) 
immunofluorescence (IF) or paraffin immunocytochemistry (IHC). 
Finally, some antibody companies are beginning to offer purchase 
agreements, which include refunds or exchange deals for antibodies 
that do not produce results, or deals offering antibodies or reduction 
in costs in return for data obtained using the purchased antibody
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an ultrathin section from a biological specimen. within the 
section compartments and structures containing the antigens 
of interest are then exposed to the labeling reagents that are 
localized by the (quantifiable) gold label. If adequate contrast-
ing with heavy metals is used, a wide range of compartments/
structures can be displayed to which the gold particles can 
then be assigned. In this process of quantitative immuno-eM 
there are two important considerations to consider. The first 
is how to sample correctly and the second is how to obtain 
quantitative readouts of the gold labeling once the section has 
been labeled. These two aspects are illustrated in Fig. 3.
while the gold signal is quantified by eM using micro-
graphs or scans, every effort should be made to make the 
final estimates representative of the intact specimen. The 
goal is to ensure that the quantities obtained from the gold 
signal or structures will faithfully report on the ‘ground 
truth’ values found inside of the organism or experimen-
tal cell culture. each micrograph usually represents a very 
tiny portion of a section, which is in turn derived from 
blocks, fragments or slices of the organ or cell pellets. 
The solution is to use rigorously applied random sampling 
protocols throughout this multistage process. Simple ran-
dom sampling ensures that all parts of the specimen have 
an equal chance of being included in the section, thereby 
giving all possible gold particles and parts of each struc-
ture an equal chance of being selected for quantification. 
However, there is an important modification to random 
sampling, which can improve the efficiency of the esti-
mates especially when it is applied to heterogeneous bio-
logical samples used in cell biology. This modification 
is called systematic uniform random sampling or SURS 
(Lucocq 2012). SURS selects an array of samples that is 
spread evenly through the specimen/section with random 
placement of the array, ensuring unbiasedness of the pro-
cedure. In cellular systems, the use of SURS often yields 
estimates that are more precise than those obtained using 
simple random sampling and this method of sampling is 
also easier to carry out. SURS can be used for sampling, 
organs, tissues, cells and organelles as well as for collec-
tion of data on the section itself [Fig. 3; see also (Lucocq 
2008) for more detailed discussion].
Once the section has been generated and labeled with 
gold reagents, the simplest way to express immunogold 
data is to assess the distribution of labeling over a range 
of organelles/compartments using a SURS-based approach. 
The principle is to count and assign each gold particle to 
an identifiable compartment (if necessary, a class referred 
Tissue/organ/culture
Slices/Blocks
Sections
Fields /scans
Gold  
Labelling
ScansFields
Quantifying gold
Imaging window
Gold
Sampling
Estimation
Point
Fig. 3  Quantifying gold labeling. In immuno-eM the experiments 
are done on animals, organs or cell cultures and the estimates of gold 
labeling should reflect the ‘ground truth’ values in these members of 
the population, with minimal bias and a high degree of precision. The 
link between what is actually measured on the eM section and the 
‘population’ is made using appropriate sampling schemes. The basic 
sampling approach is called simple uniform random but a power-
ful modification to simple random sampling that is easy to imple-
ment is systematic uniform random sampling (SURS; Lucocq 2008, 
2012). As illustrated here the systematic samples (slices, blocks, sec-
tions or microscopic fields) are spread through the objects of interest 
but always with a random start to ensure unbiasedness (see Lucocq 
2008). For example the microscopic fields (bottom left) or scans (bot-
tom right) are placed in a systematic array across the sample (10–20 
in number) starting from a random location (red arrows). estima-
tions may include distributions of gold counts over cell structures 
or the density of gold counts. Gold counts can be made most rapidly 
by scanning and viewing directly at the electron microscope or on a 
viewing screen via a CCD camera whereas density is more conveni-
ently carried out on microscopic fields. Density can be expressed as 
gold particles per unit area of structure profile or gold particles per 
unit length of membrane trace. In the example illustrated here the 
area is estimated by applying a systematic point array placed in a 
systematic random fashion. The sum of the number of points ‘land-
ing’ on features of interest multiplied by the area associated with each 
point in the lattice is an estimate of the total profile area. The density 
of gold labeling can be then estimated from the number of gold/area 
of the feature [see Lucocq (2008) for more details and for the method 
for estimation of membrane profile length]. Rather modest numbers 
of point hits and gold particles are needed (100–200 of points or gold 
particles in total per experimental condition or animal)
◂
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to as ‘non-identified’ structures may also be included). In 
one approach the ‘counts’ are carried out by viewing the 
labeled sections directly on the electron microscope view-
ing screen or via a camera display. The counts are made in 
series of scans, which are made across the labeled section 
with a random start (SURS; Fig. 3). Alternatively images 
can be recorded in a series of imaging fields or micro-
graphs (Fig. 3). In this ‘micrograph’ method, images are 
recorded at between 10 and 20 systematically placed loca-
tions across a single gold-labeled section, again with a ran-
dom start (SURS). In either approach, the magnification is 
set at a minimum value that allows clear identification of 
both the gold particles and the structures of interest. Previ-
ous work has revealed that when 10 or so compartments/
structures are considered, a total of 100–200 gold particles 
are required to produce a consistent distribution pattern 
(Lucocq et al. 2004). If more precision is required for indi-
vidual compartments, then more particles may need to be 
quantified. If one stringently follows the unbiased counting 
rules and has a consistent labeling protocol, it is striking 
how quantitatively reproducible the results are from one 
eM grid to the next, and from experiment to experiment by 
this simple approach. Such an approach conveniently pro-
vides simple and rapid way to assess any preferential distri-
bution of labeling through the initial evaluation process (as 
suggested and outlined Fig. 4).
Finally a second type of readout is gold labeling inten-
sity which can be assessed by combining gold counts with 
stereological estimations of structure profile parameters, 
such as length or area (Lucocq 2008). The gold density 
provides an important tool in assessing specificity (see next 
section).
Assessing specificity of gold labeling
To address the question of specificity, a method was 
recently developed, which utilizes cells in which an antigen 
can be knocked down (KD) or knocked out (KO; Lucocq 
and Gawden-Bone 2010; Hacker and Lucocq 2014). This 
Fig. 4  Testing antibodies for immuno-eM. Purchased antibodies 
for use in immuno-eM should be applied in the chosen labeling sys-
tem in combinations with appropriate blocking agents. In addition a 
well-established secondary marker should be used at a concentration 
that is the highest that is compatible with acceptably low background 
staining. If no signal is obtained, then the antibody concentration 
should be increased or the fixation modified to replace glutaraldehyde 
(more extensive cross-linking) with formaldehyde. Once a signal 
has been observed then a dilution series allows signal to noise to be 
assessed. The simplest method for assessing the distributions across a 
number of compartments is by counting a total of 100–200 gold par-
ticles over 10–20 micrographs (Lucocq et al. 2004); and patterns of 
preferential labeling across the dilutions series can be evaluated using 
Chi square analysis. The distribution analysis often reveals compart-
ments in which proportions of total gold label they hold increase 
as the primary antibody becomes more dilute (Lucocq and Hacker, 
unpublished observations). These compartments are likely to hold 
specific labeling. By comparison distribution analysis may reveal 
compartments over which the proportion of total labeling falls with 
dilution of the antibody. These compartments are likely to display 
‘nonspecific’ labeling. As candidate labeled compartments emerge 
then the biological/molecular information about the antigen can be 
compared and if necessary the labeling, once optimized in this way, 
can then be analyzed formally for specificity as detailed in Fig. 5
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gives an opportunity for those elements of labeling that are 
specifically related to the antigen of interest to be assessed.
The principle (see Fig. 5) uses two specimens that are 
fixed, processed, sectioned and labeled for the antigen of 
interest under identical conditions. One specimen is left 
untreated, and the other contains cells or tissues in which 
expression of the antigen has been KD or KO. In a first 
step, the density of gold labeling over a range of compart-
ments is estimated using stereological techniques under 
both conditions. The density is expressed as the number 
of gold particles per membrane profile length or orga-
nelle profile area (Griffiths et al. 1993). The next step is 
Fig. 5  evaluating specificity in immuno-eM. The principle is to 
compare the gold labeling density over a range of organelles or cell 
compartments before and after knockdown or knockout of protein 
expression. Since this comparison cannot be done sequentially on the 
same specimen (fixation and cell death occur during processing!), it 
must be done on two separate specimens which are then compared 
(Step 1). For a compartment or structure containing ‘specific labeling’ 
the gold labeling density will be higher over the control specimen 
(full expression) than over the same compartment after knockdown 
(contains less of the target protein). It is possible to subtract the labe-
ling density obtained from the KD or KO specimen from the density 
obtained from the control (Step 2). This provides the investigator with 
an estimate of labeling density that can be attributed to the antigen 
(Step 3). Notice that for a knockdown (rather than a knockout) this 
‘specific density’ will be a minimal estimate because the suppres-
sion of expression will generally be incomplete. SURS is especially 
important here because cell to cell variation in the population can 
occur and this must be ‘sensed’ or accounted for in the result. It is 
important that the processing of each specimen (control and KD/KO) 
must be as similar as possible, and rigorous sampling must be applied 
to remove error. we recommend generating specific labeling values 
from 3 to 5 individual pairs of control and knockdown samples. Once 
the specific density is known the fraction of the control labeling over 
a compartment that is specific can be found (Step 4). This ‘fraction-
specific’ expresses the likelihood that an observed gold particle is 
specific. Finally using this fraction-specific the original distribution of 
gold particles (which contains nonspecific and specific labeling) can 
now be adjusted to express the distribution of specific gold particles 
(Step 5). The distribution of specific labeling is found be multiply-
ing the fraction-specific with the original (control) counts. [see refs 
Lucocq and Gawden-Bone (2010) and Hacker and Lucocq (2014) for 
more details]
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to calculate the difference between the density values 
for control and the KD/KO for each individual organelle 
type. This generates a measure called the ‘specific den-
sity’ which assesses the portion of the control gold labe-
ling density that can be attributed to the presence of the 
antigen (notice that when the expression of the antigen is 
reduced rather than ablated the specific density can be an 
underestimate of the full extent of specific labeling for a 
particular compartment). From these data, it is then pos-
sible to assess the proportion of the labeling over each 
compartment that is attributable to the antigen and there-
fore the probability that a gold particle might represent the 
antigen (also called the fraction-specific). As an example 
if the fraction-specific is 0.8, then there is an 80 % prob-
ability that an observed gold particle located of a com-
partment is specific for the antigen of interest. Once this 
fraction-specific is known, it is straightforward to correct 
the initial labeling distribution to yield a specific labeling 
distribution profile. This is a simple matter of multiplying 
the fraction-specific with the raw (initial) gold signal for 
each compartment. Again if knockdowns are incomplete 
then the estimate of specific labeling will be an underesti-
mate. It is worth noting that the above scheme can also be 
applied for assessing specific labeling that is generated by 
expression of tagged proteins (see Lucocq and Gawden-
Bone 2010; Hacker and Lucocq 2014).
Conclusions
In summary, it must be accepted that trying to ‘prove’ that 
an antibody is specific for a given antigen is a complex, 
multi-faceted issue, associated with many pitfalls. Given 
that an increasing number of antibodies are purchased 
from companies extreme care needs to be exercised when 
selecting and testing antibodies from commercial sources; 
however, the risk of obtaining ‘duds’ may be reduced by 
paying attention to a few key pointers that we have dis-
cussed. while the long road between antigen and antibody 
is a rocky one, more judicious use of specificity controls 
by commercial companies would be highly desirable for 
improving the reliability and usefulness of these powerful 
tools for cell biology and related disciplines. At least for 
eM some effective methods are now available for estab-
lishing quantitative estimates of labeling distributions, 
and for determining more accurately how much of the 
labeling is due to the interactions of the antibody with the 
intended target. Given the commercial importance of the 
market and the extent to which researchers are dependent 
on their products, it is now high time for the companies to 
put more effort in trying to ensure that more of the esti-
mated 350,000 antibodies on the market do what they are 
claimed to do.
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